Related Experiment Video

Updated: Jan 17, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Validation of BLAST and BLAST-Mol Risk Models in Chronic Myelomonocytic Leukemia: Mayo-Humanitas Collaborative

Saubia Fathima¹, Ali Alsugair¹, Muhammad Yousuf¹

¹Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota, USA.

American Journal of Hematology

|September 25, 2025

Abstract:

The current study validates the predictive performance of the BLAST and BLAST-Mol risk models in a large two-center international cohort with a total of 1101 patients with newly diagnosed CMML.

Keywords:

NPM1 TP53 BLAST blast transformation chronic myelomonocytic leukemia risk models

More Related Videos

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

Zebrafish Model of Neuroblastoma Metastasis

Zebrafish Model of Neuroblastoma Metastasis

Published on: March 14, 2021

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

American journal of hematology·2026

Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers.

The Lancet. Haematology·2026

Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.

American journal of hematology·2026

ASSESSMENT OF THE IPSS-M IN CHRONIC MYELOMONOCYTIC LEUKEMIA.

Blood advances·2026

Drug Repurposing against the PurS Subunit of Phosphoribosylformylglycinamidine Synthase in Methicillin- and Oxacillin-Resistant Staphylococcus Aureus: In vitro and In silico Studies.

Medicinal chemistry (Shariqah (United Arab Emirates))·2026

Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients.

American journal of hematology·2026

See all related articles